Currently, the PD-L1 status is one of the mandatory biomarkers suggested in the clinical guidelines regarding metastatic NSCLC management [2, 10] and it is required to understand the association between PD-L1 expression and patients’ clinicopathological features, including the status of driver mutations. The gene discussed is CD274; the disease is non-small cell lung carcinoma.